Digital health companies seeking FDA approval must weigh access versus revenue modernhealthcare.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernhealthcare.com Daily Mail and Mail on Sunday newspapers.
5 Min Read
(Reuters) -Biogen Inc’s Alzheimer’s drug, the first new treatment for the memory-robbing disease in nearly 20 years, hit new barriers on Thursday with some large hospitals declining to use it and health insurers delaying a decision while awaiting coverage terms from Medicare.
FILE PHOTO: Aduhelm, Biogen s controversial recently approved drug for early Alzheimer s disease, is seen at Butler Hospital, one of the clinical research sites in Providence, Rhode Island, U.S. June 16, 2021. Jessica Rinaldi/Pool via REUTERS
An influential panel of medical experts also voted unanimously that there is no evidence that the drug, Aduhelm, provides a net health benefit to patients.
FDA panel does not recommend approval of roxadustat for anemia
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Subscribe
ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
Back to Healio
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Back to Healio
After more than 7 hours of discussion, the Cardiovascular and Renal Drugs Advisory Committee of the FDA voted against approval of roxadustat for the treatment of anemia due to chronic kidney disease for patients not on dialysis and on dialysis.
Message :
Required fields
July 15 (Reuters) - The rollout of Biogen Inc s
Alzheimer s drug is hitting new roadblocks as some large
hospitals decide not to use it and many health insurers await
coverage terms from Medicare, the U.S. health plan for people
aged 65 and older, before setting their own policies.
Cleveland Clinic, one of the countrys best-known health
systems, and New York s Mount Sinai Health System on Thursday
confirmed they had decided not to carry the new drug, called
Aduhelm.
Biogen shares fell 7% on Thursday, or $25.17, to $327.
Guggenheim analyst Yatin Suneja said that the slump in Biogen s
stock was due to the decision by the two hospital systems not to